Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 278

1.

Eflornithine for African sleeping sickness.

Sjoerdsma A, Schechter PJ.

Lancet. 1999 Jul 17;354(9174):254. No abstract available.

PMID:
10421331
2.

Combination chemotherapy of drug-resistant Trypanosoma brucei rhodesiense infections in mice using DL-alpha-difluoromethylornithine and standard trypanocides.

Bacchi CJ, Nathan HC, Yarlett N, Goldberg B, McCann PP, Sjoerdsma A, Saric M, Clarkson AB Jr.

Antimicrob Agents Chemother. 1994 Mar;38(3):563-9.

3.

Cure of murine Trypanosoma brucei rhodesiense infections with an S-adenosylmethionine decarboxylase inhibitor.

Bacchi CJ, Nathan HC, Yarlett N, Goldberg B, McCann PP, Bitonti AJ, Sjoerdsma A.

Antimicrob Agents Chemother. 1992 Dec;36(12):2736-40.

4.

Antimalarial polyamine analogues.

Edwards ML, Stemerick DM, Bitonti AJ, Dumont JA, McCann PP, Bey P, Sjoerdsma A.

J Med Chem. 1991 Feb;34(2):569-74.

PMID:
1995879
6.

Antitumor activity of a novel synthetic polyamine analogue, N,N'-bis-[3-(ethylamino)-propyl]-1-7-heptane diamine: potentiation by polyamine oxidase inhibitors.

Prakash NJ, Bowlin TL, Edwards ML, Sunkara PS, Sjoerdsma A.

Anticancer Res. 1990 Sep-Oct;10(5A):1281-7.

PMID:
2241104
7.

Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase.

Bitonti AJ, Byers TL, Bush TL, Casara PJ, Bacchi CJ, Clarkson AB Jr, McCann PP, Sjoerdsma A.

Antimicrob Agents Chemother. 1990 Aug;34(8):1485-90.

8.

Suppression of both antimony-susceptible and antimony-resistant Leishmania donovani by a bis(benzyl)polyamine analog.

Baumann RJ, Hanson WL, McCann PP, Sjoerdsma A, Bitonti AJ.

Antimicrob Agents Chemother. 1990 May;34(5):722-7.

9.

Clinical relevance of measuring GABA concentrations in cerebrospinal fluid.

Schechter PJ, Sjoerdsma A.

Neurochem Res. 1990 Apr;15(4):419-23. Review.

PMID:
2201926
10.

History of serotonin and serotinin disorders.

Sjoerdsma A, Palfreyman MG.

Ann N Y Acad Sci. 1990;600:1-7; discussion 7-8. Review. No abstract available.

PMID:
2252303
11.

Inhibition of glycoprotein processing and HIV replication by castanospermine analogues.

Sunkara PS, Kang MS, Bowlin TL, Liu PS, Tyms AS, Sjoerdsma A.

Ann N Y Acad Sci. 1990;616:90-6.

PMID:
2078038
12.

Anti-HIV activity of castanospermine analogues.

Sunkara PS, Taylor DL, Kang MS, Bowlin TL, Liu PS, Tyms AS, Sjoerdsma A.

Lancet. 1989 May 27;1(8648):1206. No abstract available.

PMID:
2566768
13.
14.

Reversal of chloroquine resistance in malaria parasite Plasmodium falciparum by desipramine.

Bitonti AJ, Sjoerdsma A, McCann PP, Kyle DE, Oduola AM, Rossan RN, Milhous WK, Davidson DE Jr.

Science. 1988 Dec 2;242(4883):1301-3.

PMID:
3057629
15.

Antitumor activity of norspermidine, a structural homologue of the natural polyamine spermidine.

Prakash NJ, Bowlin TL, Davis GF, Sunkara PS, Sjoerdsma A.

Anticancer Res. 1988 Jul-Aug;8(4):563-8.

PMID:
3140710
16.

A multicenter, open study of the non-sedating antihistamine, terfenadine (Seldane), in the maintenance therapy of seasonal allergic rhinitis.

Kemp JP, Falliers CJ, Fox RW, Guill MF, Segal AT, Tsai TH, Sjoerdsma A.

Ann Allergy. 1988 Apr;60(4):349-54.

PMID:
2895990
17.

African sleeping sickness in the United States. Successful treatment with eflornithine.

Petru AM, Azimi PH, Cummins SK, Sjoerdsma A.

Am J Dis Child. 1988 Feb;142(2):224-8.

PMID:
3124603
18.

Design and early clinical evaluation of selective inhibitors of monoamine oxidase.

Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A.

Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(6):967-87.

PMID:
3266532
19.

Inhibition of ornithine or arginine decarboxylase as an experimental approach to African or American trypanosomiasis.

McCann PP, Bacchi CJ, Bitonti AJ, Kierszenbaum F, Sjoerdsma A.

Adv Exp Med Biol. 1988;250:727-35. Review. No abstract available.

PMID:
3151233
20.

The effects of polyamine analogues on malaria parasites in vitro and in vivo.

Bitonti AJ, McCann PP, Sjoerdsma A.

Adv Exp Med Biol. 1988;250:717-26. No abstract available.

PMID:
2475014
21.

Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Côte d'Ivoire.

Doua F, Boa FY, Schechter PJ, Miézan TW, Diai D, Sanon SR, De Raadt P, Haegele KD, Sjoerdsma A, Konian K.

Am J Trop Med Hyg. 1987 Nov;37(3):525-33.

PMID:
3120607
22.

Antiretroviral activity of castanospermine and deoxynojirimycin, specific inhibitors of glycoprotein processing.

Sunkara PS, Bowlin TL, Liu PS, Sjoerdsma A.

Biochem Biophys Res Commun. 1987 Oct 14;148(1):206-10.

PMID:
2960321
23.

Impairment of macrophage function by inhibitors of ornithine decarboxylase activity.

Kierszenbaum F, Wirth JJ, McCann PP, Sjoerdsma A.

Infect Immun. 1987 Oct;55(10):2461-4.

24.
25.

Arginine decarboxylase inhibitors reduce the capacity of Trypanosoma cruzi to infect and multiply in mammalian host cells.

Kierszenbaum F, Wirth JJ, McCann PP, Sjoerdsma A.

Proc Natl Acad Sci U S A. 1987 Jun;84(12):4278-82.

26.

Difluoromethylornithine, an effective new treatment of Gambian trypanosomiasis. Results in five patients.

Taelman H, Schechter PJ, Marcelis L, Sonnet J, Kazyumba G, Dasnoy J, Haegele KD, Sjoerdsma A, Wery M.

Am J Med. 1987 Mar 23;82(3 Spec No):607-14.

PMID:
3103442
27.

Decarboxylated-S-adenosylmethionine excretion: a biochemical marker of ornithine decarboxylase inhibition by alpha-difluoromethylornithine.

Haegele KD, Splinter TA, Romijn JC, Schechter PJ, Sjoerdsma A.

Cancer Res. 1987 Feb 1;47(3):890-5.

28.

Enzyme-activated/mechanism-based inhibitors.

Palfreyman MG, Bey P, Sjoerdsma A.

Essays Biochem. 1987;23:28-81. Review. No abstract available.

PMID:
3331367
30.

Effects of DL-alpha-difluoromethylornithine on Leishmania donovani promastigotes.

Kaur K, Emmett K, McCann PP, Sjoerdsma A, Ullman B.

J Protozool. 1986 Nov;33(4):518-21.

PMID:
3098971
31.

Inhibition of polyamine biosynthesis by alpha-difluoromethylornithine in African trypanosomes and Pneumocystis carinii as a basis of chemotherapy: biochemical and clinical aspects.

McCann PP, Bacchi CJ, Clarkson AB Jr, Bey P, Sjoerdsma A, Schecter PJ, Walzer PD, Barlow JL.

Am J Trop Med Hyg. 1986 Nov;35(6):1153-6.

PMID:
3098121
32.

Late-stage African trypanosomiasis and eflornithine.

di Bari C, Pastore G, Roscigno G, Schechter PJ, Sjoerdsma A.

Ann Intern Med. 1986 Nov;105(5):803-4. No abstract available.

PMID:
3094420
33.

Difiuoromethylornithine in the treatment of African trypanosomiasis.

Schechter PJ, Sjoerdsma A.

Parasitol Today. 1986 Aug;2(8):223-4. No abstract available.

PMID:
15462844
34.

Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer.

Abeloff MD, Rosen ST, Luk GD, Baylin SB, Zeltzman M, Sjoerdsma A.

Cancer Treat Rep. 1986 Jul;70(7):843-5.

PMID:
3013400
35.
36.

Identification of polyamines in the cochlea of the rat and their potential role in hearing.

Schweitzer L, Casseday JH, Sjoerdsma A, McCann PP, Bartolome JV.

Brain Res Bull. 1986 Feb;16(2):215-8.

PMID:
3084042
37.

Uptake of alpha-difluoromethylornithine by Trypanosoma brucei brucei.

Bitonti AJ, Bacchi CJ, McCann PP, Sjoerdsma A.

Biochem Pharmacol. 1986 Jan 15;35(2):351-4. No abstract available.

PMID:
3080009
38.

Necessity of antibody response in the treatment of African trypanosomiasis with alpha-difluoromethylornithine.

Bitonti AJ, McCann PP, Sjoerdsma A.

Biochem Pharmacol. 1986 Jan 15;35(2):331-4.

PMID:
3080008
39.

Marked and prolonged inhibition of mammalian ornithine decarboxylase in vivo by esters of (E)-2-(fluoromethyl)dehydroornithine.

Mamont PS, Danzin C, Kolb M, Gerhart F, Bey P, Sjoerdsma A.

Biochem Pharmacol. 1986 Jan 15;35(2):159-65.

PMID:
3080004
40.

Plasmodium berghei: inhibitors of ornithine decarboxylase block exoerythrocytic schizogony.

Hollingdale MR, McCann PP, Sjoerdsma A.

Exp Parasitol. 1985 Aug;60(1):111-7.

PMID:
2990989
41.
42.
43.

Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial.

Van Nieuwenhove S, Schechter PJ, Declercq J, Boné G, Burke J, Sjoerdsma A.

Trans R Soc Trop Med Hyg. 1985;79(5):692-8.

PMID:
3938090
44.
46.

New drug combination for experimental late-stage African trypanosomiasis: DL-alpha-difluoromethylornithine (DFMO) with suramin.

Clarkson AB Jr, Bienen EJ, Bacchi CJ, McCann PP, Nathan HC, Hutner SH, Sjoerdsma A.

Am J Trop Med Hyg. 1984 Nov;33(6):1073-7.

PMID:
6439061
47.

Chemotherapeutic implications of polyamine biosynthesis inhibition.

Sjoerdsma A, Schechter PJ.

Clin Pharmacol Ther. 1984 Mar;35(3):287-300. Review. No abstract available.

PMID:
6421528
48.

Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy.

Schechter PJ, Hanke NF, Grove J, Huebert N, Sjoerdsma A.

Neurology. 1984 Feb;34(2):182-6.

PMID:
6538006
49.

Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.

Abeloff MD, Slavik M, Luk GD, Griffin CA, Hermann J, Blanc O, Sjoerdsma A, Baylin SB.

J Clin Oncol. 1984 Feb;2(2):124-30.

PMID:
6422008
50.

Successful treatment of lethal protozoal infections with the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine.

Sjoerdsma A, Golden JA, Schechter PJ, Barlow JL, Santi DV.

Trans Assoc Am Physicians. 1984;97:70-9. No abstract available.

PMID:
6442954

Supplemental Content

Loading ...
Support Center